Mrs Bonni L Klingerman, MA in Ashland, PA - Medicare Provider

Mrs Bonni L Klingerman, MA is a medicare enrolled "Psychologist - Counseling" provider in Ashland, Pennsylvania. Her current practice location is 24 Paul St, Ashland, Pennsylvania. You can reach out to her office (for appointments etc.) via phone at (570) 875-3241.

Mrs Bonni L Klingerman is licensed to practice in Pennsylvania (license number PS005600L) and she also participates in the medicare program. She accepts medicare assignments (which means she accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance) and her NPI Number is 1912995523.

Contact Information

	Mrs Bonni L Klingerman, MA
	24 Paul St, Ashland, PA 17921-9508
	(570) 875-3241
	(570) 875-3657

Healthcare Provider's Profile

Full Name	Mrs Bonni L Klingerman
Gender	Female
Speciality
Experience	Years
Location	24 Paul St, Ashland, Pennsylvania
Accepts Medicare Assignments	Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance.

Medical Education and Training:

Mrs Bonni L Klingerman attended and graduated from in

NPI Data:

NPI Number: 1912995523
Provider Enumeration Date: 10/07/2005
Last Update Date: 07/08/2007

Medicare PECOS Information:

PECOS PAC ID:
Enrollment ID:

Medical Identifiers

Medical identifiers for Mrs Bonni L Klingerman such as npi, medicare ID, medicare PIN, medicaid, etc.

Identifier	Type	State	Issuer
1912995523	NPI	-	NPPES

Medical Taxonomies and Licenses

Taxonomy	Type	License (State)	Status
103TC1900X	Psychologist - Counseling	PS005600L (Pennsylvania)	Primary

Medicare Part D Prescriber Enrollment

Any physician or other eligible professional who prescribes Part D drugs must either enroll in the Medicare program or opt out in order to prescribe drugs to their patients with Part D prescription drug benefit plans. Mrs Bonni L Klingerman is enrolled with medicare and thus, if eligible, can prescribe medicare part D drugs to patients with medicare part D benefits.

Mailing Address and Practice Location

Mailing Address	Practice Location Address
Mrs Bonni L Klingerman, MA 24 Paul St, Ashland, PA 17921-9508 Ph: (570) 875-3241	Mrs Bonni L Klingerman, MA 24 Paul St, Ashland, PA 17921-9508 Ph: (570) 875-3241

News Archive

Study: Intermittent fasting not superior to conventional calorie restriction diets

Intermittent fasting helps lose weight and promotes health. However, it is not superior to conventional calorie restriction diets, scientists from the German Cancer Research Center and Heidelberg University Hospital have found out in a study called HELENA - the largest investigation on intermittent fasting to date.

Study identifies common characteristics of pediatric vestibular schwannomas

Vestibular schwannomas, more commonly known as acoustic neuromas, are benign brain tumors that develop on the balance (vestibular) and hearing or auditory nerves leading from the inner ear to the brain.

Positive interim results from Medicago's Phase II clinical trial of H5N1 Avian Influenza VLP vaccine

Medicago Inc. a biotechnology company focused on developing highly effective and competitive vaccines based on proprietary manufacturing technologies and Virus-Like Particles (VLPs), today reported positive interim results from a Phase II human clinical trial with its H5N1 Avian Influenza VLP vaccine candidate ("H5N1 vaccine"). The vaccine was found to be safe, well tolerated and also induced a solid immune response.

Avisio signs agreement to commercialize Instant Detect diagnostic technology

Avisio, Inc. announces the signing of a definitive agreement to commercialize Instant Detect, a portable nano-based diagnostic technology. Avisio, a publicly-traded commercialization company with a mission to unlock the value of high-potential assets and transform them into high-value businesses, now has the worldwide license to commercialize Instant Detect's ground-breaking portable diagnostic sensory technology.

Eisai to commercialize lorcaserin for obesity and weight management in U.S.

Arena Pharmaceuticals, Inc. today announced that Eisai Inc. will market lorcaserin for obesity and weight management in the United States following U.S. Food and Drug Administration (FDA) approval under the terms of a marketing and supply agreement between Arena Pharmaceuticals GmbH, a wholly owned subsidiary of Arena Pharmaceuticals, Inc., and Eisai. Lorcaserin, which Arena discovered and has developed for weight management, is intended for obese patients as well as overweight patients who have at least one weight-related co-morbid condition.

Mrs Bonni L Klingerman, MA - Medicare Psychologist in Ashland, PA